AR066048A1 - Metodos y composiciones para contribuir al tratamiento de canceres - Google Patents
Metodos y composiciones para contribuir al tratamiento de canceresInfo
- Publication number
- AR066048A1 AR066048A1 ARP080101522A ARP080101522A AR066048A1 AR 066048 A1 AR066048 A1 AR 066048A1 AR P080101522 A ARP080101522 A AR P080101522A AR P080101522 A ARP080101522 A AR P080101522A AR 066048 A1 AR066048 A1 AR 066048A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- compositions
- contribute
- cancer treatment
- interferon
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- 239000000556 agonist Substances 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 229940127089 cytotoxic agent Drugs 0.000 abstract 2
- KIYSPBOGUDIMPC-SCGUGKIPSA-N 4-ala-endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)OC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)OC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](C)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CCSC)C(C)C)C1C=NC=N1 KIYSPBOGUDIMPC-SCGUGKIPSA-N 0.000 abstract 1
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 abstract 1
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 abstract 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 abstract 1
- 108050009340 Endothelin Proteins 0.000 abstract 1
- 102000002045 Endothelin Human genes 0.000 abstract 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 abstract 1
- 108010091477 IRL 1620 Proteins 0.000 abstract 1
- 102000006992 Interferon-alpha Human genes 0.000 abstract 1
- 108010047761 Interferon-alpha Proteins 0.000 abstract 1
- 102000003996 Interferon-beta Human genes 0.000 abstract 1
- 108090000467 Interferon-beta Proteins 0.000 abstract 1
- 102000008070 Interferon-gamma Human genes 0.000 abstract 1
- 108010074328 Interferon-gamma Proteins 0.000 abstract 1
- 102000000588 Interleukin-2 Human genes 0.000 abstract 1
- 108010002350 Interleukin-2 Proteins 0.000 abstract 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 101710205037 Sarafotoxin Proteins 0.000 abstract 1
- 229940009456 adriamycin Drugs 0.000 abstract 1
- 229940127093 camptothecin Drugs 0.000 abstract 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 abstract 1
- 229960004562 carboplatin Drugs 0.000 abstract 1
- 190000008236 carboplatin Chemical compound 0.000 abstract 1
- 229960004316 cisplatin Drugs 0.000 abstract 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 abstract 1
- 229960004397 cyclophosphamide Drugs 0.000 abstract 1
- 229960000975 daunorubicin Drugs 0.000 abstract 1
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 abstract 1
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 abstract 1
- 229960003668 docetaxel Drugs 0.000 abstract 1
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 abstract 1
- 229960002949 fluorouracil Drugs 0.000 abstract 1
- 229940044627 gamma-interferon Drugs 0.000 abstract 1
- 229960004768 irinotecan Drugs 0.000 abstract 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 abstract 1
- DXPHNGAMYPPTBJ-TZMIJSMNSA-N irl 1620 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CCC(O)=O)C(C)C)C1=CN=CN1 DXPHNGAMYPPTBJ-TZMIJSMNSA-N 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
- 229960000303 topotecan Drugs 0.000 abstract 1
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Marine Sciences & Fisheries (AREA)
- Molecular Biology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91177307P | 2007-04-13 | 2007-04-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066048A1 true AR066048A1 (es) | 2009-07-22 |
Family
ID=39521878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101522A AR066048A1 (es) | 2007-04-13 | 2008-04-11 | Metodos y composiciones para contribuir al tratamiento de canceres |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP2144607B1 (https=) |
| JP (1) | JP5503528B2 (https=) |
| KR (1) | KR20100016392A (https=) |
| CN (1) | CN101686960A (https=) |
| AR (1) | AR066048A1 (https=) |
| BR (1) | BRPI0810215A2 (https=) |
| CA (1) | CA2683890C (https=) |
| DK (1) | DK2144607T3 (https=) |
| ES (1) | ES2453295T3 (https=) |
| IL (1) | IL201502A (https=) |
| MX (1) | MX2009011041A (https=) |
| RU (1) | RU2009141845A (https=) |
| TW (1) | TWI439266B (https=) |
| WO (1) | WO2008127996A1 (https=) |
| ZA (1) | ZA200907083B (https=) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2502848C (en) * | 2002-10-24 | 2012-10-02 | The Board Of Trustees Of The University Of Illinois | Use of irl-1620 and paclitaxel for preventing and treating breast tumors |
| CA2598439A1 (en) * | 2005-02-22 | 2006-08-31 | The Board Of Trustees Of The University Of Illinois | Methods, compositions and articles of manufacture for contributing to the treatment of solid tumors |
-
2008
- 2008-04-10 EP EP08733184.9A patent/EP2144607B1/en not_active Not-in-force
- 2008-04-10 BR BRPI0810215-5A2A patent/BRPI0810215A2/pt not_active IP Right Cessation
- 2008-04-10 CA CA2683890A patent/CA2683890C/en active Active
- 2008-04-10 KR KR1020097023427A patent/KR20100016392A/ko not_active Ceased
- 2008-04-10 WO PCT/US2008/059949 patent/WO2008127996A1/en not_active Ceased
- 2008-04-10 DK DK08733184.9T patent/DK2144607T3/da active
- 2008-04-10 RU RU2009141845/15A patent/RU2009141845A/ru not_active Application Discontinuation
- 2008-04-10 JP JP2010503210A patent/JP5503528B2/ja not_active Expired - Fee Related
- 2008-04-10 ES ES08733184.9T patent/ES2453295T3/es active Active
- 2008-04-10 CN CN200880020158A patent/CN101686960A/zh active Pending
- 2008-04-10 MX MX2009011041A patent/MX2009011041A/es not_active Application Discontinuation
- 2008-04-11 AR ARP080101522A patent/AR066048A1/es not_active Application Discontinuation
- 2008-04-14 TW TW097113439A patent/TWI439266B/zh not_active IP Right Cessation
-
2009
- 2009-10-12 ZA ZA2009/07083A patent/ZA200907083B/en unknown
- 2009-10-13 IL IL201502A patent/IL201502A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| KR20100016392A (ko) | 2010-02-12 |
| IL201502A (en) | 2017-01-31 |
| TWI439266B (zh) | 2014-06-01 |
| ES2453295T3 (es) | 2014-04-07 |
| EP2144607A1 (en) | 2010-01-20 |
| WO2008127996A1 (en) | 2008-10-23 |
| JP2010523697A (ja) | 2010-07-15 |
| BRPI0810215A2 (pt) | 2014-10-21 |
| ZA200907083B (en) | 2011-01-26 |
| CA2683890A1 (en) | 2008-10-23 |
| AU2008240300A1 (en) | 2008-10-23 |
| MX2009011041A (es) | 2009-11-19 |
| JP5503528B2 (ja) | 2014-05-28 |
| CA2683890C (en) | 2020-01-07 |
| RU2009141845A (ru) | 2011-05-20 |
| IL201502A0 (en) | 2010-05-31 |
| DK2144607T3 (da) | 2014-04-07 |
| HK1140145A1 (en) | 2010-10-08 |
| EP2144607B1 (en) | 2014-01-08 |
| TW200904404A (en) | 2009-02-01 |
| CN101686960A (zh) | 2010-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chen et al. | Sargassum fusiforme polysaccharides inhibit VEGF-A-related angiogenesis and proliferation of lung cancer in vitro and in vivo | |
| Fazio et al. | Chemotherapy in gastroenteropancreatic (GEP) neuroendocrine carcinomas (NEC): a critical view | |
| AR062177A1 (es) | Composiciones y articulos de fabricacion para contribuir al tratamiento contra el cancer | |
| RU2016132759A (ru) | Дуокармициновые adc, демонстрирующие улучшенную противоопухолевую активность in vivo | |
| BR112015016681A8 (pt) | uso de nanopartículas compreendendo paclitaxel e uma albumina, kit, medicamento, composição e forma de dosagem unitária para tratamento de câncer pancreático | |
| EA200801132A1 (ru) | Новые улучшенные композиции для лечения рака | |
| PE20090156A1 (es) | Nuevas pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas | |
| AR049305A1 (es) | Método para tratar cancer resistente al platino con un anticuerpo her2 y un agente quimioterapéutico:gemcitabina | |
| MA32140B1 (fr) | Utilisation d'un anticorps anti-cd20 de type ii à cytotoxicité cellulaire accrue dépendant des anticorps (adcc) combiné au cyclophosphamide, à la vincristine et à la doxorubicine pour traiter les lymphomes non hodgkiniens | |
| Besançon et al. | Synergistic interaction between cisplatin and gemcitabine in neuroblastoma cell lines and multicellular tumor spheroids | |
| WO2009120697A4 (en) | Method and compositions for treatment of cancer | |
| Jiang et al. | Wnt/β-catenin signaling pathway in lung cancer stem cells is a potential target for the development of novel anticancer drugs | |
| PH12012500504A1 (en) | N-(4-((3-(2-amino-4-pyrimidinyl)-2-pyridinyl)oxy)phenyl)-4-(4-methyl-2-thienyl)-1-phthalazinamine in the treatment of antimitotic agent resistent cancer | |
| BR112022020482A2 (pt) | Combinações antitumor contendo conjugados de anticorpo anti-ceacam5 e folfiri | |
| WO2010151005A3 (ko) | 하이드록시클로로퀸을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물 | |
| KR102413412B1 (ko) | 암 치료용 트랜스-[테트라클로로비스(1h-인다졸)루테네이트(iii)]의 용도 | |
| JP2009545609A5 (https=) | ||
| ECSP109970A (es) | Mediacion de citotoxicidad de celulas que evidencian | |
| SE0401871D0 (sv) | New compositions | |
| Hernandez-Unzueta et al. | Ocoxin oral solution exerts an antitumoral effect in pancreatic cancer and reduces the stromal-mediated chemoresistance | |
| Cao et al. | Erlotinib is effective against FLT3‐ITD mutant AML and helps to overcome intratumoral heterogeneity via targeting FLT3 and Lyn | |
| AR066048A1 (es) | Metodos y composiciones para contribuir al tratamiento de canceres | |
| RU2010140611A (ru) | Комбинированное применение производных холестанола | |
| MX2009013752A (es) | Inmunocitocinas para el tratamiento del cancer en combinacion con agentes quimioterapeuticos. | |
| US20090221628A1 (en) | Compositions and methods for treatment of prostate and breast cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FB | Suspension of granting procedure |